Quantcast

Latest Natalizumab Stories

2006-03-08 11:45:00

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan Corp.'s Tysabri multiple sclerosis drug should return to the U.S. market, an advisory panel recommended on Wednesday. Tysabri sales were suspended in February 2005 after three patients developed a serious brain and spinal cord infection. Two of them died.

2006-03-08 12:35:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri should return to the market with safeguards to closely monitor patients for a potentially fatal complication, a U.S. advisory panel unanimously ruled on Wednesday. Biogen and marketing partner Elan Corp. voluntarily suspended sales in February 2005 after three patients developed a brain and spinal cord infection known as progressive multifocal leukoencephalopathy, or PML. Two of the patients...

2006-03-08 11:55:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri should return to the market with safeguards to closely monitor patients for a potentially fatal complication, a U.S. advisory panel unanimously ruled on Wednesday. Biogen and marketing partner Elan Corp. voluntarily suspended sales in February 2005 after three patients developed a brain and spinal cord infection known as progressive multifocal leukoencephalopathy, or PML. Two of the patients...

2006-03-08 10:59:41

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-08 10:50:18

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-08 10:49:50

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-08 01:23:31

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A U.S. advisory panel is set to decide on Wednesday whether to urge the return of a Biogen Idec multiple sclerosis drug that was pulled from the market last year when it was linked to a rare, life-threatening infection. The drug, Tysabri, is key for Biogen and marketing partner Elan Corp. It had been dubbed a billion-dollar-a-year seller before the safety concern arose. The companies voluntarily suspended sales in February 2005...

2006-03-07 18:30:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Multiple sclerosis patients appealed for the return of a Biogen Idec drug on Tuesday, telling U.S. advisers they would risk a life-threatening side effect for the chance at relief from disabling symptoms. Biogen and marketing partner Elan Corp voluntarily suspended sales of the drug, Tysabri, in February 2005 after three patients developed a rare brain and spinal cord infection. Two of the cases were fatal. In sometimes tearful testimony...

2006-03-01 21:15:39

By Karla Gale NEW YORK (Reuters Health) - Tysabri, a drug made by Biogen Idec and Elan Pharmaceuticals, significantly reduces the rate of disease progression in patients with relapsing multiple sclerosis (MS), according to the results of two trials reported in this week's New England Journal of Medicine. "The available drugs for MS, interferon and Copaxone, have been shown in trials to reduce relapse rate by one third," Dr. Richard A. Rudick, of the Cleveland Clinic Foundation in...

2005-11-04 17:55:36

BOSTON (Reuters) - A drug pulled from the market by the manufacturer following reports of serious side effects in patients with multiple sclerosis may help some sufferers of Crohn's disease, a new study showed. But in many instances, the drug natalizumab will be no better than a placebo, said the study published in the November 3 edition of The New England Journal of Medicine. Crohn's disease is an inflammation of the digestive tract that affects a half million Americans, many age 15...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related